Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
Previous Symbol
CUSIPN/A
Phone44-0-15-3475-6700
Debt
Debt-to-Equity Ratio1.30
Current Ratio6.17
Quick Ratio5.72
Price-To-Earnings
Trailing P/E Ratio-45.04
Forward P/E Ratio-46.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$177.03 million
Price / Sales16.57
Cash FlowN/A
Price / CashN/A
Book Value$1.24 per share
Price / Book25.43
Profitability
EPS (Most Recent Fiscal Year)($0.70)
Net Income$-61,660,000.00
Net Margins-25.37%
Return on Equity-52.72%
Return on Assets-19.72%
Miscellaneous
Employees495
Outstanding Shares93,010,000
Market Cap$2.92 billion
OptionableOptionable
Novocure (NASDAQ:NVCR) Frequently Asked Questions
What is Novocure's stock symbol?
Novocure trades on the NASDAQ under the ticker symbol "NVCR."
How were Novocure's earnings last quarter?
Novocure Ltd (NASDAQ:NVCR) posted its earnings results on Thursday, October, 25th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The medical equipment provider earned $64.76 million during the quarter, compared to analysts' expectations of $65.61 million. Novocure had a negative net margin of 25.37% and a negative return on equity of 52.72%. View Novocure's Earnings History.
When is Novocure's next earnings date?
What price target have analysts set for NVCR?
6 brokers have issued 1 year price objectives for Novocure's shares. Their forecasts range from $36.00 to $58.00. On average, they anticipate Novocure's share price to reach $46.50 in the next twelve months. This suggests a possible upside of 47.5% from the stock's current price. View Analyst Price Targets for Novocure.
What is the consensus analysts' recommendation for Novocure?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novocure.
What are Wall Street analysts saying about Novocure stock?
Here are some recent quotes from research analysts about Novocure stock:
- 1. Mizuho analysts commented, "We highlight a few key slides in the attachment. Notable points of discussions during the event revolved around potential indications for Optune in China, regulatory approval pathway and pricing dynamics. We have not taken into account the China opportunity in our model but assuming approval sometime in 2020, this could represent additional upside to our revenue forecast." (11/15/2018)
- 2. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (10/30/2018)
Has Novocure been receiving favorable news coverage?
Media coverage about NVCR stock has trended positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novocure earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the company's share price in the next few days.
Who are some of Novocure's key competitors?
Some companies that are related to Novocure include Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN), ICU Medical (ICUI), Integra Lifesciences (IART), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR) and Atrion (ATRI).
Who are Novocure's key executives?
Novocure's management team includes the folowing people:
- Asaf Danziger, Chief Executive Officer & Director
- Mike Ambrogi, Chief Operating Officer
- Wilco Groenhuysen, CFO & Principal Accounting Officer
- Eilon D. Kirson, Chief Science Officer, Head-Research & Development
- Pritesh Shah, Chief Commercial Officer
Who are Novocure's major shareholders?
Novocure's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (11.66%), BlackRock Inc. (5.11%), Baillie Gifford & Co. (3.79%), Capital World Investors (2.44%), Macquarie Group Ltd. (1.19%) and Credit Suisse AG (1.02%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Institutional Ownership Trends for Novocure.
Which institutional investors are selling Novocure stock?
NVCR stock was sold by a variety of institutional investors in the last quarter, including StepStone Group LP, Peregrine Capital Management LLC, Frontier Capital Management Co. LLC, Allianz Asset Management GmbH, Hodges Capital Management Inc., Loomis Sayles & Co. L P, Engineers Gate Manager LP and Chicago Equity Partners LLC. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Insider Buying and Selling for Novocure.
Which institutional investors are buying Novocure stock?
NVCR stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Credit Suisse AG, Baillie Gifford & Co., Capital World Investors, Wells Fargo & Company MN, Renaissance Technologies LLC and Canada Pension Plan Investment Board. View Insider Buying and Selling for Novocure.
How do I buy shares of Novocure?
Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novocure's stock price today?
One share of NVCR stock can currently be purchased for approximately $31.53.
How big of a company is Novocure?
Novocure has a market capitalization of $2.92 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-61,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Novocure employs 495 workers across the globe.
What is Novocure's official website?
How can I contact Novocure?
Novocure's mailing address is LE MASURIER HOUSE LA RUE LE MASURIER, ST. HELIER Y9, JE2 4YE. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]
MarketBeat Community Rating for Novocure (NASDAQ NVCR)
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
